Loading…
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $117M | $14M | $5M | $-1M | 4.7% | 10.2% | -58.4% |
| 2024 | $106M | $18M | $12M | $-7M | 19.1% | -6.8% | -113.0% |
| 2023 | $113M | $20M | $-93M | $17M | 587.1% | 10.9% | -4137.1% |
| 2022 | $102M | $10M | $2M | $6M | 5.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 102.29 | 113.45 | 105.76 | 116.59 |
| Operating Revenue | - | 102.29 | 113.45 | 105.76 | 116.59 |
| Cost Of Revenue | - | 4.79 | 4.64 | 3.88 | 5.42 |
| Gross Profit | - | 97.50 | 108.81 | 101.87 | 111.17 |
| Operating Expense | - | 88.29 | 89.60 | 85.64 | 99.68 |
| Research And Development | - | 16.69 | 13.78 | 12.02 | 13.70 |
| Selling General And Administration | - | 71.61 | 75.82 | 73.62 | 85.98 |
| Total Expenses | - | 93.09 | 94.24 | 89.53 | 105.10 |
| Operating Income | - | 9.20 | 19.21 | 16.23 | 11.49 |
| Total Operating Income As Reported | - | 9.20 | -67.23 | 16.16 | 11.49 |
| EBITDA | - | 10.33 | 20.33 | 17.82 | 14.01 |
| Normalized EBITDA | - | 10.33 | 116.03 | 10.72 | 11.31 |
| EBIT | - | 9.20 | 19.21 | 16.23 | 11.49 |
| Interest Income | - | 0.71 | 1.04 | 1.55 | 1.75 |
| Interest Expense | 0.12 | 0.04 | - | - | - |
| Net Interest Income | - | 0.73 | 1.04 | 1.55 | 1.75 |
| Other Non Operating Income Expenses | - | -0.52 | -1.52 | -1.66 | -1.50 |
| Other Income Expense | - | -0.52 | -97.22 | 5.44 | 1.20 |
| Interest Income Non Operating | - | 0.71 | 1.04 | 1.55 | 1.75 |
| Interest Expense Non Operating | 0.12 | 0.04 | - | - | - |
| Net Non Operating Interest Income Expense | - | 0.73 | 1.04 | 1.55 | 1.75 |
| Pretax Income | - | 9.41 | -76.96 | 23.22 | 14.44 |
| Tax Provision | - | 5.10 | 8.52 | 5.32 | 4.56 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -20.10 | 1.63 | 0.85 |
| Net Income Continuous Operations | - | 4.31 | -85.48 | 17.90 | 9.88 |
| Net Income From Continuing And Discontinued Operation | - | 2.30 | -92.93 | 12.08 | 5.03 |
| Net Income From Continuing Operation Net Minority Interest | - | 2.30 | -92.93 | 12.08 | 5.03 |
| Net Income | - | 2.30 | -92.93 | 12.08 | 5.03 |
| Net Income Common Stockholders | - | 2.30 | -92.93 | 12.08 | 5.03 |
| Net Income Including Noncontrolling Interests | - | 4.31 | -85.48 | 17.90 | 9.88 |
| Normalized Income | - | 2.30 | -17.33 | 6.61 | 3.18 |
| Diluted NI Availto Com Stockholders | - | 2.30 | -92.93 | 12.08 | 5.03 |
| Basic Average Shares | - | 76.58 | 65.83 | 85.09 | 89.34 |
| Diluted Average Shares | - | 76.58 | 65.83 | 102.29 | 103.18 |
| Reconciled Depreciation | - | 1.13 | 1.11 | 1.59 | 2.52 |
| Reconciled Cost Of Revenue | - | 4.79 | 4.64 | 3.88 | 5.42 |
| Total Unusual Items | - | 0 | -95.70 | 7.10 | 2.70 |
| Total Unusual Items Excluding Goodwill | - | 0 | -95.70 | 7.10 | 2.70 |
| Minority Interests | - | -2.01 | -7.45 | -5.81 | -4.85 |
| Special Income Charges | - | 0 | -86.44 | -0.07 | 0 |
| Gain On Sale Of Business | - | 0 | -2.71 | 0 | - |
| Other Special Charges | - | - | 83.10 | - | - |
| Gain On Sale Of Security | 0.24 | - | -9.26 | 7.17 | 2.71 |
| General And Administrative Expense | - | 17.37 | 14.66 | 16.11 | 20.80 |
| Other Gand A | - | 17.37 | 14.66 | 16.11 | 20.80 |
| Gain On Sale Of Ppe | - | 0 | -0.63 | -0.07 | 0 |
| Total Other Finance Cost | - | -0.73 | -1.04 | - | - |
| Other Operating Expenses | -0.15 | -0.84 | - | - | - |
| Selling And Marketing Expense | - | 54.24 | 61.16 | 57.51 | 65.18 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Gyre Therapeutics, Inc.this co. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Beta Bionics, Inc. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Phreesia, Inc. | PHR | $599M |
| - |
| - |
| - |
| - |
| - |
| - |
| 259.74 |
| 1.78 |
| 0.7% |
| 21.30 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $591M | -1.89 | 1.16 | -61.5% | -3.39 |
| Bioventus Inc. | BVS | $589M | 25.93 | 3.20 | 12.3% | 8.39 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| Peer Median | - | -2.50 | 2.34 | -32.3% | -3.17 | |